🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Medicines register
Registers Clinical trials Drugs API
Registers› Irish medicines ›Ranluspec 10 mg/mL solution for injection in pre-filled syringe
Medicines register · Ireland

Ranluspec 10 mg/mL solution for injection in pre-filled syringe

Authorisation EU/1/25/2012/002 · Lupin Europe GmbH

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. Published 20 Sep 2026
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from HPRA's official open dataset · Last verified · Editorial standards
Licence holder
Lupin Europe GmbH (all products →)
Active substance
Ranibizumab
Clinical trials
10 clinical trials →
Dosage form
Solution for injection in pre-filled syringe
Route of administration
Intravitreal use
ATC code
S01LA04
First authorised
10/02/2026
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Ranibizumab: supply and approvals

9 authorised products on the HPRA list contain Ranibizumab. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 26 Sep 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 26 Sep 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 26 Sep 2026)
Recent EMA authorisation
Susvimo, 18 Sep 2026, Roche Registration GmbH
Vislyfa, 15 Jul 2026 (biosimilar), Lupin Europe GmbH
Rexatilux, 19 Jun 2026 (biosimilar), Intas Third Party Sales 2005 S.L.
Ranluspec, 10 Feb 2026 (biosimilar), Lupin Europe GmbH

Registers: EU shortages · US shortages · German shortages · EMA approvals

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.